Universal Registration Document

The report records the company's first approval and launch of TWYMEEG in Japan in 2021, alongside a strategic shift toward rare metabolic diseases and continued development of its NASH and ALD pipeline. It also presents the results of an 18-month CSR formalization process, including a Board-approved three-year action plan and monitoring structure. The dedicated CSR section covers social, governance, and environmental priorities, including employee development, ethical conduct, data protection, and greenhouse-gas reduction efforts.